Finally, our study not only suggests a novel concept of differential genomic diversity as a modifier of neurodevelopmental and malignant phenotypes in those with germline PTEN variants, but also proposes potential clinical utility, especially for neurodevelopmental phenotypes, for better PHTS patient management in the future. This evidence concerns the gene PTEN and PTEN hamartoma tumor syndrome.